CartiHeal Announces Positive Interim Analysis Results of Agili-C™ IDE Study

CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today that the external and independent Endpoint Adjudication Committee (EAC) performed the first Interim Analysis (IA) on the study data following enrollment of the 250th Subject into the study. The EAC reviewed the IA safety and efficacy results and recommended to stop accrual for anticipated success. You can read more here.

Recent Posts
Featured Posts
Archive
Search By Tags

Contact Info

6 Yoni Netanyahu Street
Or Yehuda, 60376, Israel

Phone: +972 -3- 634 9990 
Fax: +972 -3- 634 9910

 

Map & Directions >>

Portfolio

Life Sciences

Software

 

 

© Peregrine Ventures  |  Terms & Conditions  |  Privacy Policy